Xavier Vila‐Farrés

2.0k total citations · 1 hit paper
25 papers, 1.5k citations indexed

About

Xavier Vila‐Farrés is a scholar working on Molecular Biology, Molecular Medicine and Microbiology. According to data from OpenAlex, Xavier Vila‐Farrés has authored 25 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Molecular Medicine and 9 papers in Microbiology. Recurrent topics in Xavier Vila‐Farrés's work include Antibiotic Resistance in Bacteria (12 papers), Antimicrobial Peptides and Activities (9 papers) and Biochemical and Structural Characterization (5 papers). Xavier Vila‐Farrés is often cited by papers focused on Antibiotic Resistance in Bacteria (12 papers), Antimicrobial Peptides and Activities (9 papers) and Biochemical and Structural Characterization (5 papers). Xavier Vila‐Farrés collaborates with scholars based in Spain, United States and Australia. Xavier Vila‐Farrés's co-authors include Jordi Vilà, Paula Espinal, Ignasi Roca, Sean F. Brady, John Chu, Ernest Giralt, Louis Cohen, Emma A. Gordon, Christophe Lemetre and Jerónimo Pachón and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Angewandte Chemie International Edition.

In The Last Decade

Xavier Vila‐Farrés

24 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Commensal bacteria make GPCR ligands that mimic human signalling molecules

2017 349 citations Louis Cohen, Daria Esterházy et al. Nature profile →

Peers

Countries citing papers authored by Xavier Vila‐Farrés

Since Specialization

Citations

This map shows the geographic impact of Xavier Vila‐Farrés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Vila‐Farrés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Vila‐Farrés more than expected).

Fields of papers citing papers by Xavier Vila‐Farrés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Vila‐Farrés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Vila‐Farrés. The network helps show where Xavier Vila‐Farrés may publish in the future.

Co-authorship network of co-authors of Xavier Vila‐Farrés

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Vila‐Farrés. A scholar is included among the top collaborators of Xavier Vila‐Farrés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Vila‐Farrés. Xavier Vila‐Farrés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro and In Vivo Characterization of Novel Cathelicidin-Based Peptides with Antimicrobial Activity Against Pseudomonas aeruginosa 2025 ·Antibiotics ·Javier Moreno, (unknown), Salvador Guardiola, Xavier Vila‐Farrés, (unknown), (unknown), Clara Ballesté‐Delpierre, Daniela Kalafatović, Ernest Giralt, María Eugenia Pachón-Ibáñez, Jordi Vilà	0
2	The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia 2024 ·The Journal of Infectious Diseases ·(unknown), (unknown), (unknown), Steven M. Swift, Xavier Vila‐Farrés, Wessam Abdelhady, Yan Q. Xiong, Dario Lehoux, Gary Woodnutt, Arnold S. Bayer, Raymond Schuch	3
3	Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase 2023 ·Microbiology Spectrum ·Xavier Vila‐Farrés, (unknown), Jun Kyun Oh, Steven M. Swift, Boudewijn L DeJonge, Jane E. Ambler, Raymond Schuch	4
4	Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance 2022 ·Frontiers in Microbiology ·Raymond Schuch, Cara Cassino, Xavier Vila‐Farrés	25
5	Synthetic-Bioinformatic Natural Product Antibiotics with Diverse Modes of Action 2020 ·Journal of the American Chemical Society ·John Chu, Bimal Koirala, (unknown), Xavier Vila‐Farrés, Melinda A. Ternei, (unknown), Dominic A. Colosimo, Sean F. Brady	44
6	Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy 2018 ·Journal of Antimicrobial Chemotherapy ·(unknown), Xavier Vila‐Farrés, Rafael Ayerbe-Algaba, Mónica Varese, Viviana Sánchez-Encinales, Núria Bayó‐Puxán, María Eugenia Pachón-Ibáñez, Meritxell Teixidò, Jordi Vilà, Jerónimo Pachón, Ernest Giralt, Younes Smani	31
7	An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds 2018 ·mSphere ·Xavier Vila‐Farrés, John Chu, Melinda A. Ternei, Christophe Lemetre, Steven Park, David S. Perlin, Sean F. Brady	18
8	Combating virulence of Gram-negative bacilli by OmpA inhibition 2017 ·Scientific Reports ·Xavier Vila‐Farrés, (unknown), Viviana Sánchez-Encinales, Mónica Varese, Rafael Ayerbe-Algaba, Núria Bayó‐Puxán, Salvador Guardiola, María Eugenia Pachón-Ibáñez, (unknown), Jesús García, Meritxell Teixidò, Jordi Vilà, Jerónimo Pachón, Ernest Giralt, Younes Smani	63
9	Commensal bacteria make GPCR ligands that mimic human signalling molecules breakdown → 2017 ·Nature ·Louis Cohen, Daria Esterházy, Seong-Hwan Kim, Christophe Lemetre, Rhiannon R. Aguilar, Emma A. Gordon, Amanda J. Pickard, Justin R. Cross, Ana B. Emiliano, Sun M. Han, John Chu, Xavier Vila‐Farrés, (unknown), Aneta Rogoz, Paula Y. Calle, Craig P. Hunter, J. Kipchirchir Bitok, Sean F. Brady	349
10	Discovery of MRSA active antibiotics using primary sequence from the human microbiome 2016 ·Nature Chemical Biology ·John Chu, Xavier Vila‐Farrés, Daigo Inoyama, Melinda A. Ternei, Louis Cohen, Emma A. Gordon, Boojala Vijay B. Reddy, Zachary Charlop–Powers, Henry Zebroski, Ricardo Gallardo‐Macias, (unknown), (unknown), Steven Park, David S. Perlin, Joel S. Freundlich, Sean F. Brady	139
11	Loss of LPS is involved in the virulence and resistance to colistin of colistin-resistantAcinetobacter nosocomialismutants selectedin vitro 2015 ·Journal of Antimicrobial Chemotherapy ·Xavier Vila‐Farrés, Mario Ferrer‐Navarro, (unknown), Sara Martí, Paula Espinal, Sushim K. Gupta, Jean‐Marc Rolain, Ernest Giralt, Jordi Vilà	25
12	A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity 2015 ·Scientific Reports ·Francesc Rabanal, Ariadna Grau-Campistany, Xavier Vila‐Farrés, Javier González-Linares, Miquel Borràs, Jordi Vilà, Ángeles Manresa, Yolanda Cajal	73
13	Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii 2015 ·European Journal of Medicinal Chemistry ·Xavier Vila‐Farrés, Rafael López-Rojas, María Eugenia Pachón-Ibáñez, Meritxell Teixidò, Jerónimo Pachón, Jordi Vilà, Ernest Giralt	23
14	CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates 2015 ·International Journal of Antimicrobial Agents ·Xavier Vila‐Farrés, (unknown), Xiaobo Gu, Paul B. Savage, Ernest Giralt, Jordi Vilà	32
15	The outer membrane porin OmpW of Acinetobacter baumannii is involved in iron uptake and colistin binding 2015 ·FEBS Letters ·Manuella Catel‐Ferreira, Sara Martí, Laurent Guillon, (unknown), Gaël Coadou, Virginie Molle, Emeline Bouffartigues, Germán Bou, (unknown), Thierry Jouenne, Xavier Vila‐Farrés, Emmanuelle Dé	54
16	Solid phase synthesis of peptide-selenoesters 2013 ·Bioorganic & Medicinal Chemistry ·(unknown), Xavier Vila‐Farrés, Paul F. Alewood, Thomas Durek	25
17	Chemical Synthesis, 3D Structure, and ASIC Binding Site of the Toxin Mambalgin‐2 2013 ·Angewandte Chemie International Edition ·Christina I. Schroeder, Lachlan D. Rash, Xavier Vila‐Farrés, K. Johan Rosengren, Mehdi Mobli, Glenn F. King, Paul F. Alewood, David J. Craik, Thomas Durek	61
18	Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group 2012 ·International Journal of Antimicrobial Agents ·J. Michael Conlon, Ágnes Sonnevend, Tibor Pál, Xavier Vila‐Farrés	26
19	The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace 2012 ·Frontiers in Microbiology ·Ignasi Roca, Paula Espinal, Xavier Vila‐Farrés, Jordi Vilà	297
20	In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii 2011 ·Clinical Microbiology and Infection ·Xavier Vila‐Farrés, Cristina García de la Mària, Rafael López-Rojas, Jerónimo Pachón, Ernest Giralt, Jordi Vilà	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact